Research Insight
Researchers Refine Nanoparticles For More Accurate Delivery Of Cancer Drugs
A new class of nanoparticles, synthesized by a UC Davis research team to prevent premature drug release, holds promise for greater accuracy and effectiveness in delivering cancer drugs to tumors. The work is published in the current issue...
Research Insight
Mylan introduces new antiepileptic drug
Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection of multiple strengths, 500mg/100ml, 1000mg/100ml and 1500mg/100ml, for intravenous use. Levetiracetam in sodium chloride injection is an antiepileptic drug indicated for adults with different...
Research Insight
Vidacare study reveals IO infusion equivalent to IV in Therapeutic Hypothermia
Vidacare's study to compare Intraosseous (IO) vascular access to infuse chilled saline as effectively as peripheral intravenous (IV) access to achieve therapeutic hypothermia showed no statistical difference between the two routes. The study was named...
Research Insight
New data confirm the benefits of early and first line treatment with Betaferon® in Multiple Sclerosis (MS)
Bayer HealthCare announced that researchers have presented data from two international long-term follow-up studies in multiple sclerosis: the BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) 8-Year Extension Study and the Betaferon® 21-Year Long-term Follow-up (LTF) Study....
Research Insight
EU study shows once-daily lisdexamfetamine dimesylate (LDX) effective for symptom control in children and adolescents with ADHD
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder (ADHD)1. LDX...
Research Insight
NIH researchers show how anti-HIV drug acts to block herpes virus
An anti-HIV drug also discovered to stop the spread of the genital herpes virus does so by disabling a key DNA enzyme of the herpes virus, according to findings by researchers at the National Institutes of Health and other...
Research Insight
New Study Shows Cialis® Significantly Improved Study Endpoints in Men
Eli Lilly and Company announced that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints, significantly improving measures of both erectile dysfunction (ED) and signs and symptoms of benign...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read